The aim of the study was to assess the effect of Cytoflavin on the severity of neurocognitive parameters in patients with chronic cerebral ischemia, as well as vertebrobasilar insufficiency with symptoms of cerebral venous circulation. The study involved 60 patients who were divided into two groups. Cytoflavin was prescribed in the treatment group: once per day in the morning, slow intravenous drip of 10.0 ml per 200 ml of 0.9% sodium chloride solution, the duration of the infusion averaged 40–60 minutes for a course of 10 days with the transition to a tablet form — 2 tablets twice per day for 30 days against the background of standard basic therapy (acetylsalicylic acid and antihypertensive drugs). Patients in the comparison group received only basic therapy. The rating scales for headache (visual analogue scale) and asthenia (asthenic state scale) were used to assess the neurological status in addition to the standard clinical and labo ratory examination. It was revealed that the main clinical and neurological manifestations in patients with symptoms of cerebral venous discirculation are headaches (48 (80%) patients) and dizziness (53 (88.3%) patients). The incidence of dizziness increased with the progression of chronic cerebral ischemia, for example, at stage I dizziness occurred in 57% of cases, at stage II — in 78%, and at stage III — in 100%. When conducting a study of the headache severity dynamics on the VAS scale, a decrease in the intensity of headaches by 1.7 times (5.68±0.62 to 3.23±0.56 points, p[1]0.5) was noted in patients who received Cytoflavin, while only a slight decrease in the intensity of pain was noted in patients of the comparison group. In addition, the inclusion of the drug in the therapy regimens for patients with this pathology showed a significant decrease in the frequency of complaints, including specific «venous» complaints, the severity of cephalgic syndrome, as well as asthenic and autonomic disorders, which had a positive effect on the patients’ quality of life. The results obtained make it possible to recommend the inclusion of the drug in the therapy regimens for patients with symptoms of cerebral venous dysfunction.
The objective of the study: to assess the structure of extrapulmonary tuberculosis in two high-burden regions (Siberia, the Far East of the Russian Federation, and the Republic of Tajikistan), with the consideration of HIV status, gender, and age of patients. Subjects and methods. A simple cohort open retrospective study was carried out based on the analysis of statistical reports from TB control institutions of the Republic of Tajikistan, Siberian and Far Eastern Federal Districts of the Russian Federation for 2018. Results. In the Siberian Federal District and Far Eastern Federal District, among extrapulmonary forms of tuberculosis, the proportion of bone and joint tuberculosis made 43.6%, urinary tuberculosis – 21.3%, and tuberculosis of central nervous system ranked third and made 17%. In Tajikistan, bone and joint tuberculosis also prevailed and made 46.0%, followed by tuberculosis of peripheral lymph nodes. In Tajikistan, among extrapulmonary tuberculosis patients, HIV positive patients made only 3.5%, while in the Siberian and Far Eastern Federal Districts, they made 36.8%. However, in the Siberian and Far Eastern Federal Districts of the Russian Federation, among HIV positive patients with extrapulmonary tuberculosis, tuberculosis of the central nervous system (38.3%) prevailed, in the Republic of Tajikistan it was tuberculosis of peripheral lymph nodes (37.9%), followed by bone and joint tuberculosis (31.0%) and abdominal tuberculosis (17.2%). Urogenital tuberculosis was in the last place in the structure of extrapulmonary tuberculosis in HIV-positive patients.
The aim of the study was to test the screening of the risk of developing cerebrovascular diseases and assess the effectiveness of cytoflavin in patients with a high risk of developing this pathology.In addition to general clinical screening (determination of glucose and cholesterol levels in the blood, control of blood pressure and pulse, determination of body mass index), assessment of neurological status using an outpatient scale for assessing chronic cerebral ischemia A.I. Fedina and assessment of the level of cognitive functions — using the Mini-KOG test. Using screening, 64 people were examined, the average age of which was 50.5 ± 11.2 years. Surveyed with a high level of risk of developing pathology for the preventive purpose was prescribed Cytoflavin: 2 tablets. 2 times a day, a course of 30 days, with dynamic monitoring of the condition.Screening for assessing the risk of developing cerebrovascular diseases has shown its effectiveness and allowed us to identify a group of patients at high risk of developing pathology. Patients of this group showed cerebral complaints, signs of asthenoneurotic syndrome and cognitive deficiency. The use of Cytoflavin helped to reduce the manifestations of asthenoneurotic syndrome and improve cognitive functions, had a positive effect on the concentration of attention, memory and thinking. However, the study was pilot in nature and its results can be used in planning further research.
Introduction. In chronic cerebrovascular diseases (CVD), neuroprotective medications, the effectiveness of which requires further study, are widely used. The effectiveness of Cytoflavinum in patients with chronic CVD was evaluated.Material and methods. The data of 60 patients (35 women and 25 men) with chronic CVD were analyzed. 30 patients, included in the main group (mean age 61 ± 5.87 years old), in addition to basic therapy (antihypertensive, antithrombotic drugs, statins), received Cytoflavinum according to the following scheme: 1 time a day in the morning intravenously 10.0 ml for 10 days, then 2 tablets 2 times a day for 30 days. 30 patients in the comparison group (mean age 59.8 ± 8.7 years old) received only basic therapy. An analysis of patient complaints, neurological status was carried out. Mini Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), Hospital Anxiety and Depression Scale (HADS) were used.Results. In the group of patients taking Cytoflavinum, there was a decrease in the frequency and intensity of headache, dizziness, an increase in MMSE score from 26.32 ± 0.86 to 28.05 ± 1.36 (p ≤ 0.05), in MoCA score from 25.35 ± 0.96 to 27.88 ± 1.13 (p ≤ 0.05), decrease in anxiety score from 8.82 ± 1.31 to 5.2 ± 2.82 (p ≤ 0.05) and decrease in HADS depression score from 8.31 ± 1.85 to 4.6 ± 3.15 (p ≤ 0.05).Conclusion. The inclusion of Cytoflavinum in the treatment regimen for patients with chronic CVD helps to reduce the frequency and intensity of headaches and dizziness, improve cognitive functions, and reduce the level of anxiety and depression.
ФГБУ «Новосибирский НИИ туберкулеза» МЗ РФ, г. Новосибирск, Россия 2 ГБОУ ВПО «Новосибирский государственный медицинский университет» МЗ РФ, г. Новосибирск, Россия 3 Новосибирский областной противотуберкулезный диспансер, г. Новосибирск, Россия 4 Национальный центр туберкулеза, заболеваний легких и торакальной хирургии, Вахдат, Республика Таджикистан Туберкулез периферических лимфатических узлов (ТПЛУ) является одной из самых частых локализаций внелегочного туберкулеза� Цель исследования: определить место ТПЛУ в структуре заболеваемости внелегочным туберкулезом в эпидемически неблагополучных соседних регионах (Сибирский и Дальневосточный федеральные округа РФ (СФО и ДФО) и Республика Таджикистан); изучить структуру этой формы туберкулеза� Материал и методы. Изучены статистические отчеты противотуберкулезных учреждений СФО и ДФО и Республики Таджикистан за 2016-2017 гг� Структуру ТПЛУ оценивали путем ретроспективного анализа амбулаторных карт больных ТПЛУ, взятых на учет в Республике Таджикистан и в областном противотуберкулезном диспансере г� Новосибирска в 2016 и 2017 г� суммарно� Результаты исследования. В СФО и ДФО РФ в 2016-2017 гг� изолированные формы внелегочного туберкулеза были диагностированы у 1 227 пациентов, из них туберкулез периферических лимфатических узлов-у 166 (13,5%) больных� Наше исследование в СФО и ДФО РФ не обнаружило статистически значимого изменения доли ТПЛУ в структуре заболеваемости внелегочным туберкулезом у пациентов с положительным и отрицательным ВИЧ-статусом� Частота ТПЛУ среди внелегочного туберкулеза в Республике Таджикистан статистически значимо выше, чем в СФО и ДФО РФ (504/1 386 и 166/1 227 соответственно, p < 0,01)� В Республике Таджикистан и в СФО и ДФО РФ в структуре ТПЛУ преобладало поражение шейных лимфатических узлов, за ним по частоте-подмышечная и паховая локализации� Разница по частоте каждой локализации между сравниваемыми территориями статистически незначима� Ключевые слова: внелегочный туберкулез, туберкулез периферических лимфатических узлов, ВИЧ-инфекция и туберкулез
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.